Anti-CD80 monoclonal antibody: galiximab

In recent years, the major approach to cancer therapy is rapidly moving away from the standard use of myelosuppressive combination chemotherapy regimens towards the testing and incorporation of more targeted therapies (e.g. monoclonal antibodies [mAbs], proteasome inhibition, anti-sense oligonucleotides, etc.). In general, these targeted therapies are associated with improved anti-tumor activity with significantly less non-specific toxicities. Nowhere is this evolution to more specific, less toxic therapy more apparent than in the field of non-Hodgkin’s lymphoma (NHL).